Skip to content
drillr.ai
Sign up

ENTA

Enanta Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$14.08
+0.43%
Ask drillr

  • Aug 10, 2026, 22:11 UTC

    Enanta Pharmaceuticals reported a Q3 2026 loss of $0.67 per share, missing the Zacks Consensus Estimate of a loss of $0.37, and compared to a loss of $0.85 per share a year ago.

    Source:

  • Jun 23, 2026, 09:10 UTC

    AbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus in the European Union.

    Source: